This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.
Roche (RHHBY) Reports Sales Numbers for First 9 Months
by Zacks Equity Research
Roche Holding AG's (RHHBY) reported sales of CHF39.4 billion in the first nine months of 2017, up 5% from the year-ago period.
BioLineRx/Roche Scan BL-8040-Tecentriq for Gastric Cancer
by Zacks Equity Research
BioLineRx (BLRX) and partner Genentech initiate a phase Ib/II study to evaluate the company's lead pipeline candidate, BL-8040, in combination with Tecentriq for treating gastric cancer.
Biogen (BIIB) Q3 Earnings: Will it Deliver a Beat Again?
by Zacks Equity Research
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
ImmunoGen to Push Leukemia Candidate into Phase I Trial
by Zacks Equity Research
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx
by Zacks Equity Research
Exelixis (EXEL) announced that the FDA has granted priority review to its supplemental New Drug Application (sNDA) for kidney cancer drug Cabomteyx.
Foreign Stock Roundup: Roche Gets FDA Nod for Zika Test, Shell to Buy NewMotion
by Swarup Gupta
Foreign markets remain undeterred by discouraging events, notching up weekly gains.
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
by Zacks Equity Research
Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.
Mylan Gets Complete Response Letter For Biosimilar Neulasta
by Zacks Equity Research
Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.
Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca
by Zacks Equity Research
Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
by Zacks Equity Research
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
by Zacks Equity Research
The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.
AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.
Allergan's sNDA for Anti-Infective Avycaz Accepted by FDA
by Zacks Equity Research
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
Prothena's Psoriasis Candidate Disappoints in Phase I Study
by Zacks Equity Research
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
by Zacks Equity Research
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Kite Pharma Triples So Far in 2017: What's Driving the Rally?
by Zacks Equity Research
Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.
Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq
by Zacks Equity Research
Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
by Zacks Equity Research
Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
by Arpita Dutt
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.
How is the Age-Related Macular Degeneration Space Faring Now?
by Zacks Equity Research
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.